Cargando…
Prognostic significance of Epstein–Barr virus DNA detection in pretreatment serum in diffuse large B‐cell lymphoma
It is still a matter of debate whether detection of Epstein–Barr virus (EBV) DNA in pretreatment serum has clinical implications for diffuse large B‐cell lymphoma. For this study, we measured EBV DNA load in pretreatment serum from 127 diffuse large B‐cell lymphoma patients without any underlying im...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714690/ https://www.ncbi.nlm.nih.gov/pubmed/26353084 http://dx.doi.org/10.1111/cas.12812 |
_version_ | 1782410361030311936 |
---|---|
author | Okamoto, Akinao Yanada, Masamitsu Miura, Hiroki Inaguma, Yoko Tokuda, Masutaka Morishima, Satoko Kanie, Tadaharu Yamamoto, Yukiya Mizuta, Shuichi Akatsuka, Yoshiki Yoshikawa, Tetsushi Mizoguchi, Yoshikazu Nakamura, Shigeo Okamoto, Masataka Emi, Nobuhiko |
author_facet | Okamoto, Akinao Yanada, Masamitsu Miura, Hiroki Inaguma, Yoko Tokuda, Masutaka Morishima, Satoko Kanie, Tadaharu Yamamoto, Yukiya Mizuta, Shuichi Akatsuka, Yoshiki Yoshikawa, Tetsushi Mizoguchi, Yoshikazu Nakamura, Shigeo Okamoto, Masataka Emi, Nobuhiko |
author_sort | Okamoto, Akinao |
collection | PubMed |
description | It is still a matter of debate whether detection of Epstein–Barr virus (EBV) DNA in pretreatment serum has clinical implications for diffuse large B‐cell lymphoma. For this study, we measured EBV DNA load in pretreatment serum from 127 diffuse large B‐cell lymphoma patients without any underlying immunodeficiency to evaluate its effects on clinical manifestations and prognosis. Anthracycline‐based chemotherapy in combination with rituximab was given as initial therapy for 119 patients (94%). Epstein–Barr virus DNA was detected in 15 patients (12%), who were older (P = 0.005) and tended to be at a more advanced disease stage (P = 0.053). They showed significantly worse progression‐free survival (PFS) and overall survival (OS) than other patients (P < 0.001 each). This effect remained significant (P = 0.004 and P = 0.027, respectively) after adjustment for age, lactate dehydrogenase, performance status, stage, and extranodal sites. The status of EBV‐encoded small RNA in situ hybridization was known for 123 patients; 6 of 8 positive patients (75%) and 9 of 115 negative patients (8%) had detectable EBV DNA in pretreatment serum. While patients positive for EBV‐encoded small RNA had significantly worse PFS and OS than negative patients (P = 0.001 and P = 0.029, respectively), EBV DNA detection in pretreatment serum was associated with poorer PFS and OS even for the 115 patients negative for EBV‐encoded small RNA (P < 0.001 each). These findings suggest that EBV DNA detection in pretreatment serum may have an adverse prognostic impact for patients with diffuse large B‐cell lymphoma. |
format | Online Article Text |
id | pubmed-4714690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-47146902016-01-22 Prognostic significance of Epstein–Barr virus DNA detection in pretreatment serum in diffuse large B‐cell lymphoma Okamoto, Akinao Yanada, Masamitsu Miura, Hiroki Inaguma, Yoko Tokuda, Masutaka Morishima, Satoko Kanie, Tadaharu Yamamoto, Yukiya Mizuta, Shuichi Akatsuka, Yoshiki Yoshikawa, Tetsushi Mizoguchi, Yoshikazu Nakamura, Shigeo Okamoto, Masataka Emi, Nobuhiko Cancer Sci Original Articles It is still a matter of debate whether detection of Epstein–Barr virus (EBV) DNA in pretreatment serum has clinical implications for diffuse large B‐cell lymphoma. For this study, we measured EBV DNA load in pretreatment serum from 127 diffuse large B‐cell lymphoma patients without any underlying immunodeficiency to evaluate its effects on clinical manifestations and prognosis. Anthracycline‐based chemotherapy in combination with rituximab was given as initial therapy for 119 patients (94%). Epstein–Barr virus DNA was detected in 15 patients (12%), who were older (P = 0.005) and tended to be at a more advanced disease stage (P = 0.053). They showed significantly worse progression‐free survival (PFS) and overall survival (OS) than other patients (P < 0.001 each). This effect remained significant (P = 0.004 and P = 0.027, respectively) after adjustment for age, lactate dehydrogenase, performance status, stage, and extranodal sites. The status of EBV‐encoded small RNA in situ hybridization was known for 123 patients; 6 of 8 positive patients (75%) and 9 of 115 negative patients (8%) had detectable EBV DNA in pretreatment serum. While patients positive for EBV‐encoded small RNA had significantly worse PFS and OS than negative patients (P = 0.001 and P = 0.029, respectively), EBV DNA detection in pretreatment serum was associated with poorer PFS and OS even for the 115 patients negative for EBV‐encoded small RNA (P < 0.001 each). These findings suggest that EBV DNA detection in pretreatment serum may have an adverse prognostic impact for patients with diffuse large B‐cell lymphoma. John Wiley and Sons Inc. 2015-10-07 2015-11 /pmc/articles/PMC4714690/ /pubmed/26353084 http://dx.doi.org/10.1111/cas.12812 Text en © 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Okamoto, Akinao Yanada, Masamitsu Miura, Hiroki Inaguma, Yoko Tokuda, Masutaka Morishima, Satoko Kanie, Tadaharu Yamamoto, Yukiya Mizuta, Shuichi Akatsuka, Yoshiki Yoshikawa, Tetsushi Mizoguchi, Yoshikazu Nakamura, Shigeo Okamoto, Masataka Emi, Nobuhiko Prognostic significance of Epstein–Barr virus DNA detection in pretreatment serum in diffuse large B‐cell lymphoma |
title | Prognostic significance of Epstein–Barr virus DNA detection in pretreatment serum in diffuse large B‐cell lymphoma |
title_full | Prognostic significance of Epstein–Barr virus DNA detection in pretreatment serum in diffuse large B‐cell lymphoma |
title_fullStr | Prognostic significance of Epstein–Barr virus DNA detection in pretreatment serum in diffuse large B‐cell lymphoma |
title_full_unstemmed | Prognostic significance of Epstein–Barr virus DNA detection in pretreatment serum in diffuse large B‐cell lymphoma |
title_short | Prognostic significance of Epstein–Barr virus DNA detection in pretreatment serum in diffuse large B‐cell lymphoma |
title_sort | prognostic significance of epstein–barr virus dna detection in pretreatment serum in diffuse large b‐cell lymphoma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714690/ https://www.ncbi.nlm.nih.gov/pubmed/26353084 http://dx.doi.org/10.1111/cas.12812 |
work_keys_str_mv | AT okamotoakinao prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT yanadamasamitsu prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT miurahiroki prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT inagumayoko prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT tokudamasutaka prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT morishimasatoko prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT kanietadaharu prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT yamamotoyukiya prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT mizutashuichi prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT akatsukayoshiki prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT yoshikawatetsushi prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT mizoguchiyoshikazu prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT nakamurashigeo prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT okamotomasataka prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma AT eminobuhiko prognosticsignificanceofepsteinbarrvirusdnadetectioninpretreatmentserumindiffuselargebcelllymphoma |